94641-22-2

Basic information

• Product Name: 6-Morpholinobenzo[d]thiazol-2-amine
• Synonyms: 6-Morpholinobenzo[d]thiazol-2-amine;6-(4-morpholinyl)-2-Benzothiazolamine;2-Amino-6-morpholinobenzothiazole
• CAS NO: 94641-22-2
• Molecular Formula: C₁₁H₁₃N₃OS
• Molecular Weight: 235.30542
• Mol File: 94641-22-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 452.5±55.0 °C(Predicted)
• Appearance: /
• Density: 1.369±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 5.33±0.10(Predicted)
• CAS DataBase Reference: 6-Morpholinobenzo[d]thiazol-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Morpholinobenzo[d]thiazol-2-amine(94641-22-2)
• EPA Substance Registry System: 6-Morpholinobenzo[d]thiazol-2-amine(94641-22-2)

Safety Data

• Hazardous Substances Data: 94641-22-2(Hazardous Substances Data)

Usage

Description

6-Morpholinobenzo[d]thiazol-2-amine is a heterocyclic amine with the molecular formula C11H12N2OS, featuring a morpholine ring and a benzothiazole ring. This chemical compound holds potential in the pharmaceutical industry and organic synthesis, attracting the attention of researchers across various scientific fields.

Uses

Used in Pharmaceutical Industry:
6-Morpholinobenzo[d]thiazol-2-amine is used as a potential candidate in drug development for its unique structural properties that may contribute to the creation of new medications.
Used in Organic Synthesis:
As a building block in organic synthesis, 6-Morpholinobenzo[d]thiazol-2-amine is utilized for constructing more complex organic compounds, facilitating advancements in chemical research and development.

Upstream product

• 2524-67-6 4-morpholino-4-yl-phenylamine 
• 1147550-11-5 ammonium thiocyanate 
• 100-00-5 4-chlorobenzonitrile 

Downstream Products

• 950769-54-7 7-morpholin-4-yl-2-(4-nitro-phenyl)-imidazo[2,1-b][1,3]benzothiazole 

Relevant articles and documents

Semicarbazone derivatives and use thereof

The invention belongs to the technical field of medicine, and relates to semicarbazone derivatives disclosed as general formula I, and geometrical isomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein the substituent groups M, R1, R2, R and n are defined in the specification. The invention also relates to a method for preparing compounds disclosed as Formula I, a pharmaceutical composition containing the compounds and application of the compounds and pharmaceutical composition in preparing drugs for treating and/or preventing cancers and other hyperplastic diseases.

Design, synthesis, and structure-activity relationships of novel benzothiazole derivatives bearing the ortho-hydroxy N-carbamoylhydrazone moiety as potent antitumor agents

A series of novel benzothiazole derivatives bearing the ortho-hydroxy N-carbamoylhydrazone moiety were designed and synthesized and their cytotoxic activities against five cancer cell lines (NCI-H226, SK-N-SH, HT29, MKN45, and MDA-MB-231) were screened in vitro. Most of them showed moderate to excellent activity against all the tested cell lines. Among them, compounds 15g (procaspase-3 EC50 = 1.42 μM) and 16b (procaspase-3 EC 50 = 0.25 μM) exhibited excellent antitumor activity with IC 50 values ranging from 0.14 μM to 0.98 μM against all cancer cell lines, which were 1.8-8.7 times more active than the first procaspase activating compound (PAC-1) (procaspase-3 EC50 = 4.08 μM). The structure-activity relationship (SAR) analyses indicated that the introduction of a lipophilic group (a benzyloxy or heteroaryloxy group) at the 4-position of the 2-hydroxy phenyl ring was beneficial to antitumor activity, and the presence of substituents containing nitrogen that are positively charged at physiological pH could also improve antitumor activity. It was also confirmed that the steric effect of the 4-position substituent of the benzyloxy group had a significant influence on cytotoxic activity.